The most successful players — both old and new — are those focusing on operational risk control rather than assay novelty.

Autonomy, by contrast, is about decision‑making and adaptation. The leap from automation to autonomy is not just more actuators; it is a system that can perceive its environment, reason about options, ...

Revvity offers comprehensive solutions designed to help accelerate laboratory workflows, assisting researchers meet targets faster and bring new therapies to market sooner. Our integrated approach ...

Fragment-based drug design (FBDD) has led to a revolution in contemporary drug discovery, facilitating a bottom-up approach to the identification and evolution of bioactive small molecules into viable ...

This article is based on a poster originally authored by Ariane Jonetz-Mentzel et al. In biopharmaceutical laboratories, there is an increasing demand for label-free, high-throughput screening based ...

Combined market-leading speed and 27 channel capacity enable maximum flexibility and data generation New fluidics and clog detection systems further simplify operation and reduce instrument downtime ...

Explore the impact of drug discovery automation in 2026, addressing complexity and improving decision-making across ...

This webinar has been postponed. Please check back for our new broadcast date. Product safety and efficacy is an integral part of conversations about the potential of cell and gene therapies, ...

The field of droplet microfluidics has emerged as a transformative approach for utilising microscale droplets as individual reaction compartments. This technology facilitates the precise manipulation ...

An open platform combines automated chemical synthesis, optical screening and AI modeling to control nanocrystal growth and ...